Table II.
Sensitization Rate (%) of AuNPs at Different Concentrations
| Final concentration of AuNPs(nM) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | 5 | 10 | 20 | ||||||
| HepG2 | B16 | HepG2 | B16 | HepG2 | B16 | HepG2 | B16 | ||
| 6-MV X-ray dose/Gy | 2 | 15.80 | 5.96 | 20.69 | 7.11 | 38.64 | 24.90 | 45.77 | 31.98 |
| 4 | 10.62 | 6.57 | 24.71 | 12.77 | 35.41 | 19.69 | 34.93 | 31.42 | |
| 6 | 18.28 | 10.78 | 21.01 | 22.27 | 41.17 | 36.27 | 43.65 | 44.57 | |
| 8 | 15.90 | 16.04 | 23.92 | 24.69 | 31.42 | 40.18 | 45.71 | 60.31 | |
| 10 | 26.41 | 13.27 | 32.49 | 27.42 | 44.73 | 47.53 | 57.39 | 53.03 | |
The sensitization rate of AuNPs was calculated as sensitization rate (%) = (viability of “IR” − viability of “IR + Au”) / viability of “IR” × 100%
AuNPs gold nanoparticles, HepG2 human hepatocellular liver carcinoma cell lines, B16 mouse melanoma cell lines